Does the media favor FENC or AVLN?

In the previous week, Adherex Technologies had 5 more articles in the media than Avalyn Pharma. MarketBeat recorded 7 mentions for Adherex Technologies and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 1.76 beat Adherex Technologies' score of 0.66 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to XERS or FENC?

In the previous week, Xeris Biopharma had 8 more articles in the media than Adherex Technologies. MarketBeat recorded 15 mentions for Xeris Biopharma and 7 mentions for Adherex Technologies. Xeris Biopharma's average media sentiment score of 1.02 beat Adherex Technologies' score of 0.66 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 12 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LBRX or FENC?

In the previous week, LB Pharmaceuticals and LB Pharmaceuticals both had 7 articles in the media. Adherex Technologies' average media sentiment score of 0.66 beat LB Pharmaceuticals' score of 0.17 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FENC or INVA?

In the previous week, Innoviva had 5 more articles in the media than Adherex Technologies. MarketBeat recorded 12 mentions for Innoviva and 7 mentions for Adherex Technologies. Innoviva's average media sentiment score of 1.69 beat Adherex Technologies' score of 0.66 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to FENC or SPTX?

In the previous week, Adherex Technologies had 2 more articles in the media than Seaport Therapeutics. MarketBeat recorded 7 mentions for Adherex Technologies and 5 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.81 beat Adherex Technologies' score of 0.66 indicating that Seaport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seaport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adherex Technologies (FENC) Competitors

$12.55 +0.24 (+1.95%)

As of 04:00 PM Eastern

Compare

FENC vs. AVLN, XERS, LBRX, INVA, and SPTX

Should you buy Adherex Technologies stock or one of its competitors? Adherex Technologies's main competitors and comparable companies include Avalyn Pharma (AVLN), Xeris Biopharma (XERS), LB Pharmaceuticals (LBRX), Innoviva (INVA), and Seaport Therapeutics (SPTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Adherex Technologies compare to Avalyn Pharma?

Adherex Technologies (NASDAQ:FENC) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Avalyn Pharma has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Avalyn Pharma's return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Avalyn Pharma	N/A	N/A	N/A

55.5% of Adherex Technologies shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Adherex Technologies currently has a consensus target price of $17.00, indicating a potential upside of 35.46%. Avalyn Pharma has a consensus target price of $60.00, indicating a potential upside of 69.30%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Avalyn Pharma is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Avalyn Pharma has lower revenue, but higher earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	9.86	-$9.74M	-$0.13	N/A
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

In the previous week, Adherex Technologies had 5 more articles in the media than Avalyn Pharma. MarketBeat recorded 7 mentions for Adherex Technologies and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 1.76 beat Adherex Technologies' score of 0.66 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Avalyn Pharma beats Adherex Technologies on 8 of the 14 factors compared between the two stocks.

How does Adherex Technologies compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Xeris Biopharma has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

In the previous week, Xeris Biopharma had 8 more articles in the media than Adherex Technologies. MarketBeat recorded 15 mentions for Xeris Biopharma and 7 mentions for Adherex Technologies. Xeris Biopharma's average media sentiment score of 1.02 beat Adherex Technologies' score of 0.66 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	12 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Xeris Biopharma has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	5.37	$550K	-$0.11	N/A
Adherex Technologies	$44.64M	9.86	-$9.74M	-$0.13	N/A

Xeris Biopharma has a net margin of -5.12% compared to Adherex Technologies' net margin of -6.09%. Xeris Biopharma's return on equity of 338.21% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Xeris Biopharma currently has a consensus price target of $12.00, indicating a potential upside of 39.70%. Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 35.46%. Given Xeris Biopharma's higher possible upside, equities analysts clearly believe Xeris Biopharma is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Xeris Biopharma beats Adherex Technologies on 10 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

LB Pharmaceuticals has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Adherex Technologies has higher revenue and earnings than LB Pharmaceuticals. Adherex Technologies is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Adherex Technologies	$44.64M	9.86	-$9.74M	-$0.13	N/A

55.5% of Adherex Technologies shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, LB Pharmaceuticals and LB Pharmaceuticals both had 7 articles in the media. Adherex Technologies' average media sentiment score of 0.66 beat LB Pharmaceuticals' score of 0.17 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals presently has a consensus target price of $49.63, indicating a potential upside of 4.43%. Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 35.46%. Given Adherex Technologies' higher probable upside, analysts plainly believe Adherex Technologies is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Adherex Technologies beats LB Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Adherex Technologies compare to Innoviva?

Adherex Technologies (NASDAQ:FENC) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Innoviva has a net margin of 81.19% compared to Adherex Technologies' net margin of -6.09%. Innoviva's return on equity of 28.03% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Innoviva	81.19%	28.03%	20.19%

Innoviva has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	9.86	-$9.74M	-$0.13	N/A
Innoviva	$411.33M	3.75	$271.17M	$4.10	5.21

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adherex Technologies has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

In the previous week, Innoviva had 5 more articles in the media than Adherex Technologies. MarketBeat recorded 12 mentions for Innoviva and 7 mentions for Adherex Technologies. Innoviva's average media sentiment score of 1.69 beat Adherex Technologies' score of 0.66 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Adherex Technologies currently has a consensus price target of $17.00, indicating a potential upside of 35.46%. Innoviva has a consensus price target of $34.75, indicating a potential upside of 62.76%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Innoviva	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Innoviva beats Adherex Technologies on 11 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Seaport Therapeutics?

Adherex Technologies (NASDAQ:FENC) and Seaport Therapeutics (NASDAQ:SPTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

55.5% of Adherex Technologies shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adherex Technologies has higher revenue and earnings than Seaport Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	9.86	-$9.74M	-$0.13	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

In the previous week, Adherex Technologies had 2 more articles in the media than Seaport Therapeutics. MarketBeat recorded 7 mentions for Adherex Technologies and 5 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.81 beat Adherex Technologies' score of 0.66 indicating that Seaport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seaport Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adherex Technologies currently has a consensus price target of $17.00, indicating a potential upside of 35.46%. Seaport Therapeutics has a consensus price target of $37.33, indicating a potential upside of 53.70%. Given Seaport Therapeutics' higher possible upside, analysts plainly believe Seaport Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

Seaport Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Seaport Therapeutics' return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Seaport Therapeutics	N/A	N/A	N/A

Summary

Adherex Technologies and Seaport Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Adherex Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FENC vs. The Competition

Export

Metric	Adherex Technologies	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$431.57M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-96.54	787.27	273.28	25.38
Price / Sales	9.86	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	10.37	12.33	12.89	6.14
Net Income	-$9.74M	$2.82B	$3.47B	$349.01M
7 Day Performance	6.63%	1.97%	-0.33%	-1.47%
1 Month Performance	30.87%	4.87%	6.51%	2.47%
1 Year Performance	41.65%	9.15%	25.19%	15.84%

Adherex Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FENC Adherex Technologies	4.4017 of 5 stars	$12.55 +1.9%	$17.00 +35.5%	+38.2%	$431.57M	$44.64M	N/A	10	Positive News Insider Trade
AVLN Avalyn Pharma	2.8615 of 5 stars	$36.51 -1.4%	$60.00 +64.3%	N/A	$1.64B	N/A	N/A	51
XERS Xeris Biopharma	3.9303 of 5 stars	$8.60 -0.9%	$12.00 +39.5%	+8.3%	$1.58B	$291.85M	N/A	290	Positive News Insider Trade
LBRX LB Pharmaceuticals	1.2368 of 5 stars	$47.89 -0.6%	$49.63 +3.6%	N/A	$1.55B	N/A	N/A	16	News Coverage
INVA Innoviva	3.2742 of 5 stars	$20.96 -1.3%	$34.75 +65.8%	+2.3%	$1.53B	$411.33M	5.11	100	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FENC) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adherex Technologies (FENC) Competitors

FENC vs. AVLN, XERS, LBRX, INVA, and SPTX

How does Adherex Technologies compare to Avalyn Pharma?

Summary

How does Adherex Technologies compare to Xeris Biopharma?

Summary

How does Adherex Technologies compare to LB Pharmaceuticals?

Summary

How does Adherex Technologies compare to Innoviva?

Summary

How does Adherex Technologies compare to Seaport Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adherex Technologies (FENC) Competitors

FENC vs. AVLN, XERS, LBRX, INVA, and SPTX

How does Adherex Technologies compare to Avalyn Pharma?

Is FENC or AVLN more profitable?

Do institutionals and insiders believe in FENC or AVLN?

Do analysts recommend FENC or AVLN?

Which has preferable valuation & earnings, FENC or AVLN?

Does the media favor FENC or AVLN?

Summary

How does Adherex Technologies compare to Xeris Biopharma?

Which has more risk and volatility, XERS or FENC?

Does the media refer more to XERS or FENC?

Do institutionals & insiders believe in XERS or FENC?

Which has higher earnings and valuation, XERS or FENC?

Is XERS or FENC more profitable?

Do analysts prefer XERS or FENC?

Summary

How does Adherex Technologies compare to LB Pharmaceuticals?

Is LBRX or FENC more profitable?

Which has preferable valuation and earnings, LBRX or FENC?

Do institutionals and insiders believe in LBRX or FENC?

Does the media refer more to LBRX or FENC?

Do analysts prefer LBRX or FENC?

Summary

How does Adherex Technologies compare to Innoviva?

Is FENC or INVA more profitable?

Which has higher valuation & earnings, FENC or INVA?

Do insiders and institutionals believe in FENC or INVA?

Which has more risk & volatility, FENC or INVA?

Does the media prefer FENC or INVA?

Do analysts prefer FENC or INVA?

Summary

How does Adherex Technologies compare to Seaport Therapeutics?

Do insiders and institutionals believe in FENC or SPTX?

Which has higher valuation & earnings, FENC or SPTX?

Does the media refer more to FENC or SPTX?

Do analysts prefer FENC or SPTX?

Is FENC or SPTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools